Disclosure: Vital Signs Today may earn a commission if you buy through links on this page, at no extra cost to you. This does not influence our evidence-based assessments. We are not a medical provider; talk to a clinician before acting on test results.
Quick answer: The fastest, lowest-friction way to start GLP-1 weight-loss treatment online in 2026 is a provider-led telehealth program that pairs a real clinical evaluation with prescription access and ongoing dose support. Of the services we reviewed, Hundred is our top pick because it combines GLP-1 access with lab work and continuous provider monitoring, which is exactly the structure that keeps people safe and on track for the months a GLP-1 actually takes to work. Ro is the strongest choice if you only want FDA-approved brand medication and help fighting your insurance. Henry Meds is the budget option built on compounded medication, a category whose legal ground shifted hard in 2025 and 2026, so read the section below before you assume “compounded” means “cheap and fine.”
A licensed clinician, not a website and not this article, decides whether a GLP-1 is appropriate for you. This page is education, not medical advice.
| Service | Best for | Pricing | Visit |
|---|---|---|---|
| Hundred | GLP-1 with lab monitoring | Membership + meds | View › |
| Ro | Brand-name + insurance help | $149/mo membership + meds | View › |
| Henry Meds | Flat all-in monthly pricing | From ~$179-$397/mo all-in | View › |
What GLP-1 telehealth actually is, and who it is for
GLP-1 telehealth is a way to get evaluated, prescribed, and monitored for a GLP-1 weight-loss medication entirely online. You fill out a medical history, sometimes upload labs or get them ordered, talk to a licensed clinician by video or secure message, and if you qualify the medication ships to your door. The platform is an access and convenience layer. It is not the drug maker, and it is not a replacement for your primary care doctor.
GLP-1 stands for glucagon-like peptide-1, a gut hormone the body releases after you eat. The medications in this class imitate that hormone. They slow how fast your stomach empties, blunt appetite, and quiet the food-related signals in the brain that drive cravings and “food noise.” That is why people on these drugs report eating less without the white-knuckle willpower battle that defines most diets.
This route makes sense for a specific person: someone who meets the medical criteria for obesity treatment, wants the convenience of remote care, and is willing to commit to a months-long, clinician-supervised process rather than a quick fix. It is a poor fit for anyone hunting for a prescription with no real evaluation, anyone who wants to lose ten vanity pounds, or anyone with a history that makes these drugs risky (more on that below). The honest test is simple: if a service will sell you a GLP-1 without genuinely checking whether you should be on one, that is a red flag, not a feature.
The big 2026 change: brand versus compounded GLP-1
This is the single most important thing to understand before you spend a dollar, and it is the thing most articles still get wrong. The legal landscape for GLP-1 medications changed dramatically between 2024 and 2026.
Why “compounded” was everywhere in 2023 and 2024
When demand for Ozempic, Wegovy, Mounjaro, and Zepbound exploded, the FDA placed the active ingredients (semaglutide and tirzepatide) on its official drug shortage list. Under federal law, a shortage opens a door: licensed compounding pharmacies are temporarily allowed to make their own versions of a drug that is in short supply. That is how a wave of telehealth companies began selling compounded semaglutide and tirzepatide for a fraction of the brand price. It was legal because of the shortage, not because compounded copies are normally permitted.
The shortages ended, and the door started closing
The FDA declared the tirzepatide shortage resolved in December 2024 and the semaglutide shortage resolved in February 2025. Once a shortage ends, the legal basis for mass compounding of that drug disappears. The agency set wind-down deadlines through 2025 for compounders to stop producing essentially-copies of the now-available brand drugs.
In April 2026 the FDA went further. It proposed leaving semaglutide, tirzepatide, and liraglutide off the “503B bulks list,” the list that governs large outsourcing facilities. In plain terms, the large-scale industrial compounding that fed the cheap-GLP-1 boom is being shut off, with the rule expected to be finalized later in 2026. The FDA also clarified that these ingredients no longer sit on either the shortage list or the bulks list, which removes the clinical-need justification outsourcing facilities had been leaning on.
What is actually legal now
Compounded semaglutide and tirzepatide are no longer broadly, routinely available the way they were in 2024. The narrow exceptions that remain are genuinely narrow. A traditional 503A pharmacy may still compound a patient-specific version only when a prescriber documents a real clinical reason the commercial product cannot meet the patient’s needs. The examples the FDA points to are things like a documented allergy to an inactive ingredient in the brand product, a need for a dose strength that is not commercially made, or a documented impairment that makes the standard pen impossible to use. The FDA has also signaled it will not pursue a 503A pharmacy that fills four or fewer prescriptions of an essentially-copy product per month, but each of those still requires a documented, patient-specific “significant difference” determination by the prescriber. Cost savings alone is not a legally sufficient reason to compound.
The practical takeaway for you as a buyer: if a 2026 telehealth service is still advertising cheap compounded semaglutide or tirzepatide to the general public as its main product, that is a category under heavy regulatory pressure. It is not automatically illegal in your specific case, but it is far shakier ground than it was two years ago, and the supply could be disrupted at any time. Compounded products are not FDA-approved, meaning they have not been evaluated by the FDA for safety, effectiveness, or manufacturing quality. The FDA has logged hundreds of adverse-event reports tied to compounded GLP-1s, many of them dosing errors from patients drawing the wrong amount out of multi-dose vials. None of that means every compounded product is dangerous, but it does mean the safety net is thinner.
The plot twist that makes this whole debate less urgent than it was: the brand manufacturers cut their cash prices hard. The gap between brand and compounded has narrowed to the point where, for many people, brand is now the smarter buy. That brings us to cost.
How we evaluated these providers
We did not rank these services on marketing polish. We weighed five practical factors that determine whether a program is safe, legitimate, and worth the money:
- What is actually prescribed. FDA-approved brand medication versus compounded, given the 2026 legal shift. Brand carries regulatory certainty; compounded carries regulatory risk.
- Depth of the clinical evaluation. Does a licensed provider genuinely review your history, and is there lab work? A real eligibility check is the difference between medicine and a vending machine.
- Ongoing support. GLP-1 dosing is titrated upward over months, and side effects need managing. A program that disappears after the first shipment is selling a product, not care.
- Total, honest cost. Flat all-in pricing versus a membership fee stacked on top of separately-billed medication. We flag where the headline number hides the real one.
- Insurance handling. Whether the service fights to get your medication covered, which can swing your out-of-pocket cost by hundreds of dollars a month.
Hundred, our top pick for GLP-1 with real monitoring
Hundred is our primary recommendation because its structure matches what a GLP-1 journey actually requires: a clinical evaluation, lab work, prescription access, and ongoing provider support over the long haul rather than a one-and-done sale. GLP-1 treatment is not a transaction, it is a months-long medical process, and the programs that build in monitoring are the ones that catch problems early and keep people losing weight safely.
If you want a single starting point that treats weight loss as supervised medical care rather than a quick prescription, this is where we would send a friend first. Check current eligibility and pricing directly, since program details and medication options can change.
Telehealth weight and metabolic program: provider-led GLP-1 care with lab work and ongoing support.
Ro, best for brand-name medication and insurance help
Ro made a deliberate choice that looks smart in 2026: it offers only FDA-approved brand GLP-1 medications (Wegovy, Zepbound, Ozempic, and the oral Wegovy pill), not compounded copies. That means you sidestep the entire compounding legal mess. The Ro Body membership runs about $149 per month on a monthly plan, dropping to roughly $74 per month if you prepay annually, with a discounted first month. Critically, the medication is billed separately on top of that membership; the fee buys you the care layer, not the drug.
The standout feature is the insurance concierge. Ro’s team handles benefits verification, prior authorizations, and the paperwork that usually buries patients. If your plan covers a GLP-1, that help can be worth far more than the membership costs. If your plan does not cover it, Ro can route you to cash-pay brand options like Zepbound vials. The trade-off is that you are paying a recurring membership fee separate from the medication, so the all-in monthly number is higher than a flat compounded plan, in exchange for FDA-approved drugs and insurance muscle.
Telehealth program offering only FDA-approved brand GLP-1 (Wegovy, Zepbound, Ozempic) with an insurance concierge.
Henry Meds, the budget compounded option (with a caveat)
Henry Meds built its model on compounded GLP-1s at a flat, all-in monthly price that bundles medication, provider visits, supplies, and shipping with no separate membership fee. Reported pricing has ranged from around $179 per month for compounded liraglutide up to roughly $297 to $397 per month for compounded semaglutide, with multi-month bundles bringing the injectable cost down toward $197 to $247. The simplicity is real: one price, everything included, async visits.
The caveat is the whole point of this article. Henry Meds prescribes compounded semaglutide, tirzepatide, and liraglutide, not brand drugs. After the 2025 shortage resolutions and the 2026 FDA proposals, that is exactly the category under the most regulatory pressure. The medications are made in FDA-registered facilities but are not FDA-approved. For a specific patient with a documented clinical reason, compounded can still be legitimate, but as a general-public discount path it is on shakier legal footing than it was, and supply could shift. We include it here so you can compare honestly, and we would steer most readers toward brand options now that brand prices have fallen.
Telehealth program with compounded GLP-1 at a flat monthly price that includes medication, visits, and shipping.
How much GLP-1 costs in 2026
Here is the development that reshaped this market: the brand manufacturers slashed their cash prices, mostly through direct-to-consumer programs that ship single-dose vials instead of pre-filled pens.
- Eli Lilly (Zepbound, tirzepatide) via LillyDirect: self-pay vials have been priced roughly in the $299 to $499 per month range depending on dose and on staying within the refill window. The lowest tiers (2.5 mg and 5 mg) sit around $299 to $399, with a flat ceiling around $449 for higher doses for qualifying self-pay patients. Vials require drawing the dose with a syringe, which is how Lilly keeps the price down versus the pen.
- Novo Nordisk (Wegovy, semaglutide) via NovoCare: the self-pay injectable pen has been offered around $349 per month, with promotional pricing near $199 per month for the first months for new patients. The oral Wegovy pill has been priced lower, in roughly the $149 to $299 range depending on dose. Novo has also signaled further list-price cuts ahead.
- Telehealth program fees: separate from the drug, a membership like Ro’s runs about $74 to $149 per month. Flat compounded plans like Henry’s fold the medication into one price. Hundred prices as a membership plus medication; confirm current numbers on its site.
- Insurance: if your plan covers a GLP-1 for obesity, your copay can be a fraction of cash price, which is precisely why a service with a real insurance concierge can pay for itself. Coverage for weight loss (as opposed to diabetes) remains inconsistent across plans, so verification matters.
The headline: brand GLP-1 at roughly $300 to $500 a month cash is no longer dramatically more expensive than compounded, and it comes with FDA approval and supply stability. For a lot of people in 2026, that math now favors brand.
How the drugs work, expected results, and timeline
Semaglutide (the molecule in Ozempic and Wegovy) and tirzepatide (the molecule in Mounjaro and Zepbound) mimic gut hormones that regulate appetite and blood sugar. Tirzepatide hits two receptors (GLP-1 and GIP) rather than one, and in head-to-head and trial data it tends to produce somewhat greater average weight loss, though individual results vary widely.
Expect a slow build, not an overnight change. Providers titrate the dose upward over weeks to months to limit side effects, so the early weeks are about tolerance, not dramatic results. In clinical trials, meaningful weight loss accrues over roughly 16 to 72 weeks. Average results in major trials have landed in the mid-teens percent of body weight for semaglutide and higher for tirzepatide, but trial averages are not promises, and real-world results depend on dose, adherence, diet, and activity.
One sobering, well-documented point: when people stop the medication, much of the lost weight tends to return. These drugs manage a chronic condition the way blood-pressure medication does, rather than curing it. That is why the long-term plan you build with your provider matters more than the first month on the scale.
Side effects and safety, and who should not use a GLP-1
The most common side effects are gastrointestinal: nausea, vomiting, diarrhea, constipation, and reflux, usually worst during dose increases and often easing with time. Slow titration and dietary adjustments help. Less common but more serious risks include pancreatitis, gallbladder problems, and dehydration from severe GI symptoms.
GLP-1 medications are not appropriate for everyone. They carry a boxed warning related to thyroid C-cell tumors seen in rodent studies, so they are contraindicated for people with a personal or family history of medullary thyroid carcinoma or with Multiple Endocrine Neoplasia syndrome type 2. They are generally not used during pregnancy or breastfeeding, or in people with a history of pancreatitis, and they require caution with certain other conditions and medications. This is exactly why a legitimate evaluation matters: a real clinician screens for these before prescribing. Tell whoever prescribes about every medication and condition you have, and loop in your own doctor.
How to start, step by step
- Check eligibility honestly. GLP-1 obesity treatment is generally aimed at adults with a BMI of 30 or higher, or 27 or higher with a weight-related condition such as type 2 diabetes, high blood pressure, or sleep apnea. Know your number before you start.
- Pick your lane. If you want FDA-approved brand medication and possible insurance coverage, start with a brand-only program. If you want supervised, lab-backed care as your anchor, start with our top pick.
- Complete the intake. Fill out the medical history fully and truthfully. Omitting a condition to “qualify” defeats the safety check that protects you.
- Do the clinical evaluation. Talk to the licensed provider and get any recommended labs. This is where appropriateness is decided.
- Start low and titrate. Expect to begin at a low dose and step up gradually. Report side effects rather than pushing through them.
- Use the support and plan for the long term. Stay in contact for dose adjustments, pair the medication with nutrition and activity, and discuss a maintenance plan with your provider, because stopping abruptly tends to undo progress.
Ready to see whether you qualify under a program that builds in monitoring?
Frequently asked questions
Is compounded semaglutide or tirzepatide legal in 2026?
Only in narrow circumstances. The FDA declared the tirzepatide shortage resolved in December 2024 and the semaglutide shortage resolved in February 2025, which ended the broad legal basis for compounding these drugs. In 2026 the FDA also proposed shutting off large-scale outsourcing-facility compounding. A traditional pharmacy may still make a patient-specific compounded version only when a prescriber documents a genuine clinical reason the brand product cannot meet, such as a documented ingredient allergy or a dose not commercially available. Cost savings alone is not a valid reason.
Do I need insurance to get a GLP-1 online?
No. Many people pay cash. Brand manufacturers now offer self-pay programs (Zepbound vials roughly $299 to $499 per month, Wegovy pen around $349 per month with promotions), and telehealth programs offer cash-pay paths. Insurance, when it covers GLP-1 for obesity, can drop your cost substantially, which is why a service with an insurance concierge can be worth the fee.
What BMI do I need to qualify?
The general medical threshold for GLP-1 obesity treatment is a BMI of 30 or higher, or 27 or higher if you also have a weight-related condition such as type 2 diabetes, high blood pressure, or sleep apnea. The prescribing clinician makes the final call based on your full picture.
How fast will I see results?
Slowly and steadily, measured in months, not days. Doses are titrated upward over weeks to limit side effects, and meaningful weight loss in clinical trials accrued over roughly 16 to 72 weeks. Results vary widely by person, dose, and adherence.
Can I get a GLP-1 without a prescription?
No. GLP-1 weight-loss medications are prescription drugs in the United States and require evaluation by a licensed provider. Any seller offering them with no prescription and no evaluation is operating outside the law and outside basic safety, and the product may not be what it claims to be.
Brand versus compounded, which should I choose now?
For most people in 2026, brand. Brand drugs are FDA-approved for safety, effectiveness, and quality, and manufacturer cash prices have fallen to roughly $300 to $500 per month, close enough to compounded that the regulatory certainty is usually worth it. Compounded can still make sense for a specific patient with a documented clinical need, but as a general discount path it now sits on shaky legal ground.
What is the difference between semaglutide and tirzepatide?
Semaglutide (Ozempic, Wegovy) acts on one hormone receptor (GLP-1). Tirzepatide (Mounjaro, Zepbound) acts on two (GLP-1 and GIP) and tends to produce somewhat greater average weight loss in trials. Which is right for you depends on your health profile, tolerance, and what your provider recommends.
Will the weight come back if I stop?
Often, yes, at least partially. Research consistently shows that stopping a GLP-1 tends to reverse much of the weight loss. These medications manage weight as an ongoing condition rather than curing it, so plan for the long term and discuss a maintenance strategy with your provider before you start.
Is it safe to get a GLP-1 through telehealth?
It can be safe when a licensed provider genuinely reviews your medical history, screens for contraindications, and a legitimate pharmacy fills the prescription. Risk rises sharply with services that skip a real evaluation or push multi-dose vials without clear dosing guidance. When in doubt, involve your own doctor.
What does a telehealth GLP-1 program actually include?
The better programs include a medical intake, a licensed provider evaluation, lab work or lab review where appropriate, the prescription itself, home delivery, and ongoing support for dose titration and side effects. Thinner programs sell little more than a prescription and a shipment, which is why we weight monitoring and support so heavily.
Disclosure: Vital Signs Today may earn a commission if you buy through links on this page, at no extra cost to you. This does not influence our evidence-based assessments. We are not a medical provider; talk to a clinician before acting on test results.
Reviewed by the VST Editorial Board. Vital Signs Today provides evidence-based health education, not medical advice. GLP-1 medications are prescription drugs with real risks; consult a licensed clinician before starting, stopping, or changing any treatment. Prices and program details cited here can change; verify current terms with each provider.
